Related Experiment Video
Updated: Jan 7, 2026
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.5K
Biological Features of Gastric Cancer After Neoadjuvant Chemotherapy
Yuko Tamura1, Masanori Oshi2, Hiroki Kondo3
1Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Anticancer Research
|December 30, 2025
Summary
Neoadjuvant chemotherapy (NAC) response in gastric cancer is linked to tumor proliferation and immune cell infiltration. Five specific genes (ZNF296, RASSF10, EXOC3L1, KIAA0895, GALNTL1) show reduced expression in non-responders, suggesting potential biomarkers.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Gastric cancer prognosis is poor, with limited use of neoadjuvant chemotherapy (NAC) in Japan.
- Docetaxel-based regimens show international promise, but their biological mechanisms require elucidation.
Purpose of the Study:
- To identify key biological differences between pathological responders and non-responders to docetaxel-based NAC.
- To investigate the transcriptomic profile of gastric tumors treated with NAC.
Main Methods:
- Transcriptomic analysis of tumor sections from 24 gastric cancer patients treated with docetaxel plus S-1 (DS) or docetaxel with cisplatin plus S-1 (DCS) as NAC.
- Comparison of gene expression profiles between responsive and non-responsive groups.
Main Results:
- Non-responders exhibited worse prognosis, enriched proliferation-related gene sets, and lower infiltration of CD8+ and CD4+ effector memory cells and dendritic cells.
- No significant differences were observed in key immune pathways like interferon-γ and interferon-α response.
- Significantly lower expression of five genes (ZNF296, RASSF10, EXOC3L1, KIAA0895, GALNTL1) was found in the non-response group.
Conclusions:
- Lack of NAC response is associated with increased tumor proliferation, poor antitumor immunity, and reduced expression of ZNF296, RASSF10, EXOC3L1, KIAA0895, and GALNTL1.
- These five genes are potential biomarkers for predicting NAC efficacy and novel therapeutic targets in gastric cancer.
